Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mabwell (Shanghai) Bioscience Co., Ltd.
Atavistik Bio, Inc
Novartis
Novartis
NiKang Therapeutics, Inc.
Rush University Medical Center
Kivu Bioscience Inc.
Alterome Therapeutics, Inc.
BeOne Medicines
Aktis Oncology, Inc.
Exelixis
Eli Lilly and Company
Arcus Biosciences, Inc.
OncoTherapy Science, Inc.
Radiopharm Theranostics, Ltd
Accent Therapeutics
Seagen Inc.
Bayer
ProteinQure Inc.
IntoCell, Inc
Tizona Therapeutics, Inc
Canadian Cancer Trials Group
Washington University School of Medicine
Normunity AccelCo, Inc.
Eli Lilly and Company
NiKang Therapeutics, Inc.
Institute of Cancer Research, United Kingdom
H. Lee Moffitt Cancer Center and Research Institute
SystImmune Inc.
City of Hope Medical Center
Emory University
Boundless Bio, Inc.
Eli Lilly and Company
Novartis
Royal Marsden NHS Foundation Trust
AbbVie
University of Southern California
Eli Lilly and Company
Dana-Farber Cancer Institute
Seagen Inc.
Cellectar Biosciences, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Fusion Pharmaceuticals Inc.
Innate Pharma